Hire Sanjay Tatoba Dhumal, a pharma consultant specializing in Drug Development and FDA Inspections. See services offered, experience summary, and connect via apicule.
Based in: India
Willing to work in: Global
Consultant Type: Independent Consultant
Expertise summary: Sanjay Tatoba Dhumal is an independent pharmaceutical quality and regulatory consultant specializing in biologics and FDA inspection readiness. His experience spans monoclonal antibodies, insulin analogues, recombinant proteins, vaccines, and sterile pharmaceutical products. He has held senior quality leadership roles with Shilpa Biologicals and Wockhardt Biotech, alongside earlier positions with Pfizer, Hospira, Lupin, Strides, and Orchid. His work includes establishing quality systems for greenfield biologics facilities, supporting technology transfer, overseeing validation activities, and preparing manufacturing operations for international regulatory inspections. Through his consulting work, he helps pharmaceutical and biotechnology companies strengthen quality processes, address compliance gaps, and prepare clinical and commercial manufacturing operations for regulatory assessment. - Show More


Sanjay supports biologics manufacturing through quality oversight, technology transfer, validation planning, and commercial readiness assessments. His experience covers monoclonal antibodies, insulin analogues, recombinant proteins, and vaccines. He has established quality systems for greenfield biologics facilities and coordinated transfers for clinical and commercial batches. He also advises on comparability studies and process harmonization to support product commercialization.

Sanjay helps pharmaceutical and biotechnology facilities prepare for FDA inspections through quality system assessments, internal audit frameworks, documentation improvements, and team training. His experience includes establishing inspection-ready systems and supporting FDA inspections across sterile and biologics operations. He helps clients identify gaps in CAPA, deviations, change control, validation, and data integrity practices and implement improvements that support ongoing readiness.